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IMPORTANCE Sleeve gastrectomy is increasingly used in the treatment of morbid obesity, but
its long-term outcome vs the standard Roux-en-Y gastric bypass procedure is unknown.
OBJECTIVE To determine whether there are differences between sleeve gastrectomy and
Roux-en-Y gastric bypass in terms of weight loss, changes in comorbidities, increase in quality
of life, and adverse events.
DESIGN, SETTING, AND PARTICIPANTS The SwissMulticenter Bypass or Sleeve Study
(SM-BOSS), a 2-group randomized trial, was conducted from January 2007 until November
2011 (last follow-up in March 2017). Of 3971 morbidly obese patients evaluated for bariatric
surgery at 4 Swiss bariatric centers, 217 patients were enrolled and randomly assigned to
sleeve gastrectomy or Roux-en-Y gastric bypass with a 5-year follow-up period.
INTERVENTIONS Patients were randomly assigned to undergo laparoscopic sleeve
gastrectomy (n = 107) or laparoscopic Roux-en-Y gastric bypass (n = 110).
MAIN OUTCOMES ANDMEASURES The primary end point was weight loss, expressed as
percentage excess bodymass index (BMI) loss. Exploratory end points were changes in
comorbidities and adverse events.
RESULTS Among the 217 patients (mean age, 45.5 years; 72%women; mean BMI, 43.9) 205
(94.5%) completed the trial. Excess BMI loss was not significantly different at 5 years: for
sleeve gastrectomy, 61.1%, vs Roux-en-Y gastric bypass, 68.3% (absolute difference, −7.18%;
95% CI, −14.30% to −0.06%; P = .22 after adjustment for multiple comparisons). Gastric
reflux remission was observedmore frequently after Roux-en-Y gastric bypass (60.4%) than
after sleeve gastrectomy (25.0%). Gastric reflux worsened (more symptoms or increase in
therapy) more often after sleeve gastrectomy (31.8%) than after Roux-en-Y gastric bypass
(6.3%). The number of patients with reoperations or interventions was 16/101 (15.8%) after
sleeve gastrectomy and 23/104 (22.1%) after Roux-en-Y gastric bypass.
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B ariatric surgery is themost effective treatment for pa-tients with morbid obesity. Until recently, Roux-en-Ygastric bypass was regarded as the standard bariatric
procedure. However, sleeve gastrectomy is being performed
with increasing frequencydespite the lackof evidence regard-
ing its long-term efficacy.1 The sleeve gastrectomy procedure
is technically easier, faster to perform, and potentially safer
comparedwithRoux-en-Ygastricbypass.However,muchmore
data on clinical andmetabolic long-term outcomes are avail-
ableontheRoux-en-Ygastricbypassprocedure.Earlyandmid-
term results of sleeve gastrectomy showed potential benefit,
but only a limited number of randomized studies have com-
pared outcomes of sleeve gastrectomy and Roux-en-Y gastric
bypass head to head, most of which were underpowered
because of low patient numbers, short follow-up, or both.2-6
The purpose of this trial was to compare differences be-
tween sleevegastrectomyandRoux-en-Ygastric bypass in the
treatment of morbid obesity in terms of weight loss, changes
in comorbidities, quality of life, and adverse events.
Methods
The studywas conducted in accordancewith theprinciples of
the Declaration of Helsinki,7 approved by each local ethical
committee, and registered at the clinical trials registry of the
National Institutes of Health. All patients gave written in-
formed consent.
Study Design
The trial protocol and statistical analysis plan are available in
Supplement1. Inbrief, thetrialwasa2-group, randomized,mul-
ticenter study including 217 patients with morbid obesity at 4
bariatric centers in Switzerland and conducted from January
2007 until November 2011, with final follow-up inMarch 2017
(Figure1).Oneofthe4centerswasaddedin2008toincreasethe
sizeof the studypopulationanddecrease theenrollment time.
Participants
Following the general criteria for bariatric surgery in
Switzerland, study inclusion criteria were a bodymass index
(BMI) greater than 40 or a BMI greater than 35 with the pres-
ence of at least 1 comorbidity (BMI calculated as weight in
kilograms divided by height in meters squared), an age of 18
to 65 years, and failure of conservative treatment for 2 years.
Exclusion criteria were contraindications for major abdomi-
nal surgery,previousbariatric surgery, severesymptomaticgas-
troesophageal reflux disease despite medication, large hiatal
hernia, expected dense adhesions at the level of the small
bowel, need for endoscopic follow-up of the duodenum, and
history of inflammatory bowel disease.
Randomization
A central, computer-based block randomization (block size
of 20) with sealed envelopes was carried out. There was no
blindingwith regard to the type of operation: patients aswell
as physicians anddietitians assessing follow-updatawere in-
formed about the procedure performed.
Interventions
In sleeve gastrectomy, the majority of the stomach is verti-
cally resectedandatube-shapedremnant is left alongthe lesser
curvature. In Roux-en-Y gastric bypass, a small gastric pouch
is connected to the small intestine, bypassing the stomach,
duodenum, and the proximal part of the jejunum. The 2 in-
terventionswere standardized across the centers and all pro-
cedures were performed laparoscopically. The surgical inter-
ventions, number of participating surgeons, and centers are
described inmoredetail inTable 1 andTable 2 and in eAppen-
dix 1 in Supplement 2.
Outcomes
All patients were assessed as part of a routine follow-up pro-
gram in the outpatient clinic of each participating center ac-
cording to Swiss guidelines and were seen on a regular sched-
ule 6weeks and 3, 6, 9, 12, 18, and 24months postoperatively.
Thereafter,patientswere seenannually.Theprimaryendpoint
of the studywasweight loss, definedaspercentageexcessBMI
loss (100×[baselineBMI−follow-upBMI]/[baselineBMI−25]),
over a 5-year period. Weight was measured at each visit. Ex-
ploratory clinical end pointswere (1) changes in comorbidities
(arterial hypertension, type 2 diabetes, dyslipidemia, obstruc-
tive sleep apnea, gastroesophageal reflux, arthralgia, depres-
sion, andhyperuricemia; assessedbyaphysicianat eachvisit);
(2)qualityof lifeassessedontheGastrointestinalQualityofLife
Index (36 items; scale range, 0-144 points; most desirable op-
tion:4points; leastdesirableoption:0points;meanscoreamong
healthyindividuals, 125.8points)8andtheBariatricAnalysisand
Reporting Outcome System quality-of-life (BAROS QoL) score
(5 items;scalerange,−3to3points;mostdesirableoption:1point
for 1 item, 0.5 point for the other 4 items; least desirable op-
tion: −1 point for 1 item, −0.5 point for the other 4 items)9,10;
(3) the rate of perioperative and long-termmorbidity necessi-
tating reoperation or intervention; and (4) mortality. Meta-
bolic effects andmechanismswere previously analyzed as ex-
ploratory end points in subgroups.11-15 Definitions of
comorbidities are described in eTable 1 in Supplement 2.
The following exploratory end points mentioned in the
original studyprotocol (Supplement 1) arenot reportedherein:
durationof theoperation (previouslypublished16), costs (analy-
sis abandonedbecauseof changes in reimbursement systemin
Switzerland), and quality of food intake (analysis abandoned
because of inappropriate questionnaire). Other exploratory
Key Points
Question Is there a difference in weight loss between
laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y
gastric bypass in patients with morbid obesity?
Findings In this randomized clinical trial that included 217 adults
with morbid obesity, percentage excess bodymass index loss in
patients undergoing sleeve gastrectomy compared with gastric
bypass was 61.1% vs 68.3% after 5 years, a difference that was not
statistically significant after adjustment for multiple comparisons.
Meaning This study did not find a significant difference in weight
loss between sleeve gastrectomy and gastric bypass.
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outcomes included BMI changes, weight loss, percentage of
originalweight loss, andcutpointsof25%,50%,and75%inex-
cessBMI loss (scaleofweight lossdivided intoquartiles follow-
ing the classification of the BAROS score10).
Statistical Analysis
Thepowerestimation forexcesspercentageBMI losswasbased
on the assumptions of equal variances in both treatment
groups, a pooled standard deviation of 20%, a base effect of
excess BMI loss at 5 years of 50% in the control group and a
minimum detectable difference of an additional 10%, and an
α=.05. A sample size of 100 patients per groupwas estimated
toprovideapowerof94%to reject thenullhypothesisof equal
meansusing a 2-sided, 2-sample equal-variance t test.17,18 Ac-
cording to ameta-analysis, a difference of 10% in excess BMI
loss resulted in a superior type2diabetes remission ratewhen
comparing gastric banding, Roux-en-Ygastric bypass, andbil-
iopancreatic diversion.19 Therefore, a minimal difference of
10% excess BMI loss was considered clinically relevant.
All comparisons between treatment groups are reported
as absolute differences with 95% confidence intervals and
P values. Missing follow-up data were imputed by a multiple
imputation technique using the fully conditional specifica-
tionmethod based onMarkov chainMonte Carlo simulation.
From the imputed data set, the other weight-related param-
eters were calculated.
Longitudinal data were first analyzed for all of the
follow-up time points jointly by a linearmixed-effectsmodel
analysisusing typeof intervention, center, sex,andvisits (time)
as fixed effects and age and initial BMI as random effects, in
which visits represented the repeated measures of the longi-
tudinal data. This approachwasused instead of the originally
planned repeated-measures analysis of variance tobetter cap-
ture the data structure of the repeated measures. Afterward,
pairwise comparisons between treatment groups were per-
formed for each time point separately, with multiple un-
paired t tests with subsequent step-down Bonferroni-Holm
correction for P-value adjustment for multiple comparisons.
For the analysis of adverse events and comorbidities, pro-
portionswere comparedbyχ2 andFisher exact tests as appro-
priate. Exploratory outcomes were compared between base-
line and 5-year follow-up and for thedifference betweenboth
time points. All statistical tests were 2-sided and P < .05 was
considered statistically significant.
SPSS forWindows, version 25 (IBM), and R, version 3.4.2
(RProject forStatisticalComputing,RFoundation;http://www
.r-project.org/; chisq.test, fisher.test, andprop.test)wereused
for data analysis (see original statistical plan in Supplement 1
and eAppendix 2 in Supplement 2).
Results
Of the 225 patients randomized, a total of 217 were included
and randomly assigned to undergo either sleeve gastrectomy
(n = 107) or Roux-en-Y gastric bypass (n= 110). Eight patients
were excluded from the analysis: 7 patients chose to undergo
later operation (when the enrollment phase had already been
concluded) and 1 patient crossed over from the Roux-en-Y
gastric bypass group to the sleeve gastrectomy group be-
cause of unexpected dense adhesions of the jejunum, which
were detected intraoperatively. Baseline demographic char-
acteristics are shown in Table 1. After 5 years, data from 205
patients (94.5%) were available for evaluation. Ten patients
were lost to follow-up, 2 patients died (1 within 30 days of
operation because of a surgical complication and 1 after 2.5
yearsbecauseof lymphoma) (Figure 1).Missingdata forweight
was 0% at baseline, 0.46% at 1 year, 25.8% at 2 years, 3.2% at
3 years, 31.8% at 4 years, and 5.5% (including 12 dropouts)
at 5years.All reportedPvalues are corrected formultiple com-
parisons unless indicated otherwise.
Primary Outcome
Overall, both treatments significantly reducedpercentage ex-
cessBMI lossover theobservationperiod,withsignificantover-
alldifferencesbetweenthegroupswithoutadjustment formul-
tiple comparisons (P = .03). However, in the primary analysis
that adjusted for multiple comparisons, there were no statis-
tically significantdifferences inpercentageexcessBMI loss for
sleeve gastrectomy comparedwithRoux-en-Y gastric bypass,
respectively, at 1 year (72.4% vs 76.7%; absolute difference,
−4.22%; 95% CI, −9.96% to 1.51%; P = .30); at 2 years (71.9%
vs 77.4%; absolute difference, −5.57%; 95% CI, −11.84% to
0.71%; P = .25); at 3 years (69.5% vs 73.9%; absolute differ-
ence, −4.32%; 95% CI, −10.59% to 1.59%; P = .30); at 4 years
Figure 1. Participant Flow Through the SwissMulticenter Bypass
or Sleeve Study
3971 Patients assessed for eligibility
3746 Excluded (did not meet
inclusion criteria
or declined to participate) 
225 Randomized
6 Lost to follow-up 4 Lost to follow-up
2 Died
1 Surgical complication
1 Lymphoma
101 Included in analysis
11 Excluded
6 Lost to follow-up
5 Patient choice to delay
operation until after study
enrollment concluded
104 Included in analysis
9 Excluded
4 Lost to follow-up
2 Died
1 Did not undergo intervention
as randomized
2 Patient choice to delay
operation until after study
enrollment concluded
112 Randomized to undergo
laparoscopic sleeve gastrectomy
112 Underwent laparoscopic
sleeve gastrectomy as
 randomized
113 Randomized to undergo
laparoscopic Roux-en-Y gastric
bypass
112 Underwent Roux-en-Y
gastric bypass as randomized
1 Did not undergo Roux-en-Y
gastric bypass (crossed over
to sleeve gastrectomy
because of intraoperative
technical difficulties)
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(64.1%vs70.8%;absolutedifference,−6.73%;95%CI,−13.25%
to −0.20%; P = .22); and at 5 years (61.1% vs 68.3%; absolute
difference, −7.18%; 95% CI, −14.30% to −0.06%; P = .22)
(Figure 2). Results without adjustment for multiple compari-
sons were not significantly affected by center (P = .19; for ab-
solute differences among centers, see eTables 2 and 3 in
Supplement 2), age (absolute difference, 0.25%; 95% CI,
0.004%-0.50%;P = .28), and sex (absolutedifference, 5.45%;
95% CI, −0.72% to 11.61%; P = .08), but initial BMI (absolute
difference, −1.44; 95% CI, −1.94 to −0.94; P < .001) signifi-
cantly contributed to the percentage excess BMI loss.
There was a significant trend (P < .001) for a linear de-
crease in excess BMI loss over the follow-up period for both
treatment groups (for sleeve gastrectomy, slope, −3.05% [95%
CI,−4.53%to−1.58%]peryear;P < .001; intercept, 77.0%[95%
CI, 72.07%-81.85%]; P < .001 and for Roux-en-Y gastric by-
pass, slope, −2.34% [95% CI, −3.72% to −0.97%] per year;
P = .001; intercept, 80.4% [95% CI, 75.9%-85.0%]; P < .001).
Exploratory Outcomes
At baseline, 26 (25.7%) of 101 in the sleeve gastrectomy group
and 28 (26.9%) of 104 in the Roux-en-Y gastric bypass group
had type 2 diabetes; 6 (23.1%) of 26 in the sleeve gastrectomy
groupand6(21.4%)of28 in theRoux-en-Ygastricbypassgroup
were receiving insulin treatment.At 5years after surgery, com-
plete remissionwas seen in 16 (61.5%) of 26 in the sleeve gas-
trectomy group vs 19 (67.9%) of 28 in the Roux-en-Y gastric
bypass group (absolute difference, −0.04%; 95% CI, −0.37%
to 0.28%; P > .99). Marked amelioration of glycemic control
was seen after 5 years compared with baseline, with no sig-
nificant differences between the treatment groups in fasting
glucose (sleevegastrectomy, 114.1mg/dL, vsRoux-en-Ygastric
bypass, 101.1mg/dL; absolute difference, 13.0mg/dL; 95%CI,
−7.50 to 33.49 mg/dL; P = .21) or hemoglobin A1c (sleeve gas-
trectomy, 6.2%, vs Roux-en-Y gastric bypass, 5.9%; absolute
difference, 0.30%;95%CI, −0.06% to0.82%;P = .09), uncor-
rected for multiple comparisons (Table 3 and Table 4).
Before surgery, 68 (67.3%) of 101 in the sleeve gastrec-
tomy group and 53 (51%) of 104 in the Roux-en-Y gastric by-
pass grouphaddyslipidemia. Complete remissionwas seen in
29 (42.6%)of68 in the sleevegastrectomygroupvs 33 (62.3%)
of 53 in the Roux-en-Y gastric bypass group 5 years after sur-
gery (absolutedifference,−0.19%;95%CI,−0.38%to−0.003%)
(Table 3).
Significantameliorationwasseenafter5years for total and
high-density lipoprotein cholesterol, ratio of total choles-
terol to high-density lipoprotein cholesterol, low-density li-
poprotein cholesterol, and triglycerides in both groups
(Table4). Although therewasno significant difference in total
andhigh-density lipoprotein cholesterol and triglycerides be-
tween the groups, the ratio of total cholesterol to high-
density lipoprotein cholesterol (sleeve gastrectomy, 3.3, vs
Roux-en-Y gastric bypass, 3.0; absolute difference, 0.38; 95%
CI, 0.06-0.70; P = .02) and low-density lipoprotein choles-
terol (sleevegastrectomy, 116.1mg/dL,vsRoux-en-Ygastricby-
pass, 101.1 mg/dL; absolute difference, 14.95 mg/dL; 95% CI,
3.91-25.99 mg/dL; P = .008) were both significantly better 5
years after Roux-en-Y gastric bypass (Table 4).
At the time of surgery, 44 (43.6%) of 101 in the sleeve gas-
trectomy group and 48 (46.2%) of 104 in the Roux-en-Y
gastricbypassgroupexperiencedsomedegreeofgastroesopha-
geal reflux disease. After 5 years, remission of reflux symp-
tomswasseen in 11 (25%)of44 in thesleevegastrectomygroup
and 29 (60.4%) of 48 in the Roux-en-Y gastric bypass group
(absolute difference, −0.36%; 95% CI, −0.57% to −0.15%;
P = .002) andworsening of symptomswasmore often seen in
the sleeve gastrectomy group (14/44 [31.8%] vs 3/48 [6.3%];
absolute difference, 0.36%; 95% CI, 0.13%-0.59%; P = .006).
Inaddition, 18 (31.6%)of57patientswhohadnogastroesopha-
geal reflux disease at baseline reported de novo reflux symp-
toms5yearsafter sleevegastrectomy,whereas thiswas thecase
only in 6 (10.7%) of 56 patients who underwent Roux-en-Y
gastric bypass (absolute difference, 0.31%; 95% CI, 0.08%-
0.54%; P = .01) (Table 3).
Quality of life increased significantly in both groups be-
tweenbaseline and5years. Therewereno statistically signifi-
cant differences between the 2 groups on the Gastrointesti-
nal Quality of Life Index (sleeve gastrectomy, 113.6 points, vs
Roux-en-Y gastric bypass, 117.9 points; absolute difference,
−4.33 points; 95% CI, −15.07 to 6.40 points; P = .42) and the
BAROSQoL score (1.4 vs 1.7 points, respectively; absolute dif-
ference, −0.25 points; 95% CI, −0.64 to 0.14 points; P = .20),
uncorrected for multiple comparisons (Table 4).
Table 1. Baseline Demographic Characteristicsa
Characteristics
Sleeve Gastrectomy
(n = 107)
Roux-en-Y
Gastric Bypass
(n = 110)
Age, mean (SD), y 43.0 (11.1) 42.1 (11.2)
Female 77 (72.0) 79 (71.8)
Weight, mean (SD), kg 123.5 (19.4) 124.8 (19.8)
Body mass index, mean (SD)b 43.6 (5.2) 44.2 (5.3)
Type 2 diabetes 26 (24.3) 28 (25.5)
Dyslipidemia 72 (67.3) 56 (50.9)
Gastroesophageal reflux 47 (43.9) 51 (46.4)
Hypertension 67 (62.6) 65 (59.1)
Obstructive sleep apnea 51 (47.7) 46 (41.8)
Back or joint pain 65 (60.7) 75 (68.2)
Hyperuricemia 16 (15) 11 (10)
Depression 21 (19.6) 12 (10.9)
a Data are expressed as No. (%) of participants unless otherwise indicated.
bCalculated as weight in kilograms divided by height in meters squared
Table 2. Interventions per Surgeon
Surgeons
No. (%)
Sleeve Gastrectomy (n = 107)
Roux-en-Y Gastric
Bypass (n = 110)
A 63 (58.9) 60 (54.5)
B 24 (22.4) 21 (19.1)
C 11 (10.3) 6 (5.5)
D 3 (2.8) 9 (8.2)
E 4 (3.7) 11 (10.0)
F 2 (1.9) 3 (2.7)
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Adverse Events
Early Complications (0-30Days After Surgery)
Onepatient inthesleevegastrectomygroupand5patients inthe
Roux-en-Y gastric bypass group required additional surgical or
endoscopicinterventionintheperioperativeperiod(1/107[0.9%]
vs5/110 [4.5%]; absolutedifference,−0.19%;95%CI,−0.57%to
0.20%; P = .66, uncorrected formultiple comparisons). In the
sleevegastrectomygroup, 1obstructionof thegastricsleevewas
treatedbylaparoscopicrevision. IntheRoux-en-Ygastricbypass
group,2patientsneededsurgical evacuationof intraabdominal
abscess formation and 1 for pleural empyema, and 1 patient
hadanobstructionof thebiliopancreatic limb.Onepatienthad
a leakage at the gastrojejunostomywith a complicated course,
which eventually led tomultiorgan failure and death.
Late Complications
Fifteen (14.9%)of 101patients in the sleevegastrectomygroup
and 18 (17.3%)of 104 in theRoux-en-Ygastric bypass group re-
quired additional surgical or endoscopic interventions from
postoperative day 30 through 5-year follow-up (absolute dif-
ference,−0.05%;95%CI,−0.25%to0.16%;P = .77,uncorrected
formultiple comparisons). In the sleeve gastrectomygroup, 9
patientsunderwentconversion toRoux-en-Ygastricbypassbe-
causeof severegastroesophageal refluxdisease, 5patientshad
insufficient weight loss (3 converted to biliopancreatic diver-
sion duodenal switch and 2 to Roux-en-Y gastric bypass), and
1patienthad incisionalhernia repair.Amongthe9patientswho
converted to Roux-en-Y gastric bypass during the 5 years of
follow-up, 1 haddevelopeddenovoBarrettmucosa, 1 hadhia-
tal herniation of the sleeve, and 7 experienced reflux esopha-
gitis thatwasnotresponsivetoprotonpumpinhibitortreatment.
In the Roux-en-Y gastric bypass group, 2 patients had
smallbowelobstruction,9patientsweretreatedfor internalher-
nia (ofwhich5hadprimary closureof thedefects and4didnot
atthetimeofprimaryoperation),and2patientswithinsufficient
weight loss underwent renewal of the gastrojejunostomywith
Figure 2. Percentage Excess BMI Loss After Sleeve Gastrectomy (n=101) or Roux-en-Y Gastric Bypass (n=104)
Over 5 Years of Follow-up
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Time course of superimposed
cumulative individual values of
percentage excess bodymass index
(BMI) loss over the 5-year period
after surgery. Circles indicate mean
values at 1, 2, 3, 4, and 5 years after
surgery. Missing values were imputed
for number of participants at each
time point. Bodymass index is
calculated as weight in kilograms
divided by height in meters squared.
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Table 3. Changes in Comorbidities at 5 Years
Comorbiditiesa
No. (%)
Absolute Difference, %
(95% CI)b
P Value
Sleeve Gastrectomy
(n = 101)
Roux-en-Y Gastric
Bypass (n = 104) Unadjusted Adjustedc
Type 2 Diabetes
Comorbidity present at baseline 26/101 (25.7) 28/104 (26.9) −0.02 (−0.18 to 0.15) .97d
Remission 16 (61.5) 19 (67.9) −0.04 (−0.37 to 0.28) .77d >.99
Improved 4 (15.4) 2 (7.1) 0.22 (−0.28 to 0.45) .40e >.99
Unchanged 3 (11.5) 3 (10.7) 0.03 (−0.42 to 0.49) >.99e >.99
Worsened 3 (11.5) 4 (14.3) −0.05 (−0.49 to 0.48) >.99e >.99
De novo development
of comorbidity
0 3/76 (3.9) −0.50 (−1.00 to 0.08) >.99e
Dyslipidemia
Comorbidity present at baseline 68/101 (67.3) 53/104 (51) 0.17 (0.02 to 0.39) .03d
Remission 29 (42.6) 33 (62.3) −0.19 (−0.38 to −0.003) .03d .09
Improved 28 (41.2) 16 (30.2) 0.12 (−0.08 to 0.32) .21d .36
Unchanged 11 (16.2) 4 (7.5) 0.20 (−0.09 to 0.48) .18e .36
Worsened 0 0
De novo development
of comorbidity
3/33 (9.1) 6/51 (11.8) −0.07 (−0.46 to 0.32) >.99e
Gastroesophageal Reflux
Comorbidity present at baseline 44/101 (43.6) 48/104 (46.2) −0.03 (−0.17 to 0.12) .71d
Remission 11 (25) 29 (60.4) −0.36 (−0.57 to −0.15) .0006d .002
Improved 4 (9.1) 3 (6.3) 0.10 (−0.36 to 0.56) .71e .94
Unchanged 15 (34.1) 13 (27.1) 0.08 (−0.16 to 0.33) .47d .94
Worsened 14 (31.8)a 3 (6.3) 0.36 (0.13 to 0.59) .002e .006
De novo development
of comorbidity
18/57 (31.6) 6/56 (10.7) 0.31 (0.08 to 0.54) .01d
Hypertension
Comorbidity present at baseline 64/101 (63.4) 64/104 (61.5) 0.02 (−0.12 to 0.16) 0.90d
Remission 40 (62.5) 45 (70.3) −0.09 (−0.29 to 0.11) 0.34d >.99
Improved 16 (25) 14 (21.9) 0.04 (−0.18 to 0.27) .68d >.99
Unchanged 4 (6.3) 2 (3.1) 0.17 (−0.30 to 0.65) .67e >.99
Worsened 4 (6.3) 3 (4.7) 0.08 (−0.38 to 0.53) >.99e >.99
De novo development
of comorbidity
2/37 (5.4) 2/40 (5) 0.01 (−0.49 to 0.51) >.99e
Obstructive Sleep Apnea
Comorbidity present at baseline 48/101 (47.5) 43/104 (41.3) 0.06 (−0.08 to 0.21) .45d
Remission 22 (45.8) 19 (44.2) 0.02 (−0.21 to 0.24) .87d >.99
Improved 24 (50) 22 (51.2) −0.01 (−0.23 to 0.21) .91d >.99
Unchanged 0 1 (2.3) −0.53 (−1.00 to 0.08) .47e >.99
Worsened 2 (4.2) 1 (2.3) 0.14 (−0.54 to 0.83) >.99e >.99
De novo development
of comorbidity
5/53 (9.4) 1/61 (1.6) 0.39 (−0.01 to 0.79) >.99e
Back or Joint Pain
Comorbidity present at baseline 60/101 (59.4) 72/104 (69.2) −0.11 (−0.26 to 0.05) .19d
Remission 33 (55) 35 (48.6) 0.06 (−0.12 to 0.25) .46d >.99
Improved 23 (38.3) 22 (30.6) 0.09 (−0.11 to 0.28) .35d >.99
Unchanged 3 (5) 13 (18.1) −0.30 (−0.55 to −0.06) .03e .12
Worsened 1 (1.7) 2 (2.8) −0.12 (−0.79 to 0.54) >.99e >.99
De novo development
of comorbidity
0 0
Hyperuricemia
Comorbidity present at baseline 15/101 (14.9) 10/104 (9.6) 0.12 (−0.11 to 0.35) .35d
Remission 15 (100) 10 (100) 0.12 (−0.11 to 0.35) .35d .35
Improved 0 0
Unchanged 0 0
Worsened 0 0
De novo development
of comorbidity
0 0
(continued)
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pouch resizing. Furthermore, 3 patients experienced severe
dumpingandunderwent reoperation, twicebypouch revision
and once by bypass reversal. In addition, 1 patient needed in-
cisional hernia repair, and in another patient laparoscopy was
performedforendoscopicaccess to thegastric remnant.Weight
loss to below a BMI of 18, hypoalbuminemia, and life-
threatening complications or deaths associatedwith the inter-
ventionsdidnotoccurup to5years after surgery. In total (early
and late complications), 16 patients in the sleeve gastrectomy
groupand23 in theRoux-en-Ygastricbypassgrouprequired re-
visions (absolutedifference,−0.10%;95%CI,−0.29%to0.09%;
P = .33) (Table 5).
Post Hoc Outcomes
All P values reported under post hoc outcomes are uncor-
rected for multiple comparisons because comparisons were
made only for baseline vs 5 years.
The percentage of patients with a percentage excess BMI
loss greater than 50% at 5 years was 68.3% in the sleeve gas-
trectomygroupand76%in theRoux-en-Ygastricbypassgroup
(absolutedifference,−0.1%;95%CI,−0.26%to0.07%;P = .28).
ApercentageexcessBMI lossgreater than75%wasobserved in
31.7%vs40.4%, respectively (absolutedifference,0.09%;95%
CI,−0.06%to0.25%;P = .21).ApercentageexcessBMI loss less
than25%wasobserved in9.9%of sleeve gastrectomypatients
and3.8%ofRoux-en-Ygastric bypasspatients (absolutediffer-
ence, −0.24%; 95% CI, −0.52% to 0.05%; P = .10).
MeanBMI decreased significantly frombaseline to 5 years
after operation (in the sleeve gastrectomy group, from 43.5 to
32.5, and in the Roux-en-Y gastric bypass group, from 44.3
to 31.6; P < .001 for both groups). Therewas no significant dif-
ference in BMI at 5 years between the interventions (absolute
difference,0.91; 95%CI, −0.77 to2.6;P = .29).Meanweight re-
duction was not significantly different between the groups at
5 years (sleeve gastrectomy, 33.0 kg, vs Roux-en-Y gastric by-
pass, 36.6 kg; absolute difference, 3.6 kg; 95% CI, −1.8 kg
to 9.0 kg; P = .19). In both groups, weight loss nadir was
reached between 1 and 2 years after surgery (eFigure 1 in
Supplement 2). Mean weight loss expressed as percentage of
originalweight losswas lower in the sleeve gastrectomygroup
vs the Roux-en-Y gastric bypass group at 5 years (sleeve gas-
trectomy, 25.0%, vs Roux-en-Y gastric bypass, 28.6%; abso-
lute difference, −3.7%; 95%CI, −6.7% to −0.6%;P = .02) (eFig-
ure 2 in Supplement 2).
Discussion
In this trial including 217morbidly obese patients randomized
to undergo either laparoscopic sleeve gastrectomy or
Roux-en-Y gastric bypass, no significant difference in percent-
age excessBMI losswas found5years after surgery in analyses
that adjusted for multiple comparisons. Furthermore,
obesity-associated comorbidities, including type 2 diabetes
anddyslipidemia,were reducedafterbothprocedures,with the
exception of gastroesophageal reflux disease, which was
achieved more often after Roux-en-Y gastric bypass. More-
over, worsening of reflux symptoms was found more fre-
quently in patientswho underwent sleeve gastrectomy. There
wasnostatistically significantdifferencebetween the2groups
in the increase of quality of life or in the number of reopera-
tions or interventions.
This trial did not detect a statistically significant differ-
ence inweight losswhenmeasured as percentage excess BMI
loss,which is in contrast to2 recentmeta-analyses comparing
the 2 interventions, both of which found greater weight loss
with Roux-en-Y gastric bypass.20,21 However, both meta-
analyses includedmainlynonrandomizedstudieswithoutap-
propriatecontrols,andinmoststudies,definitionsfor thereso-
lution of comorbidities were not reported. Also, the few
randomized studies that were included had either a shorter
follow-up time or included fewer patients comparedwith the
current trial. When this study was designed, it was common
to report outcomes from bariatric surgery as percentage ex-
cess weight or BMI loss. In recent years, the preferred means
of reportingweight loss followingbariatric surgery is percent-
ageweight loss relative to original bodyweight.22 In this trial,
posthocanalysisofpercentagebodyweight losscomparedwith
Table 3. Changes in Comorbidities at 5 Years (continued)
Comorbiditiesa
No. (%)
Absolute Difference, %
(95% CI)b
P Value
Sleeve Gastrectomy
(n = 101)
Roux-en-Y Gastric
Bypass (n = 104) Unadjusted Adjustedc
Depression
Comorbidity present at baseline 21/101 (20.8) 12/104 (11.5) 0.17 (−0.03 to 0.37) .11d
Remission 8 (38.1) 6 (50) −0.11 (−0.51 to 0.28) .51d >.99
Improved 8 (38.1) 6 (50) −0.11 (−0.51 to 0.28) .51d >.99
Unchanged 0 0
Worsened 5 (23.8) 0 0.43 (0.13 to 0.73) .13e .39
De novo development
of comorbidity
7/80 (8.8) 2/92 (2.2) 0.33 (−0.01 to 0.45) >.99e
a Remission: no symptoms and/or nomedication; improvement: fewer
symptoms and/or less medical treatment or medications; unchanged: same
symptoms and equivalent therapy; worsened: more symptoms or increase in
therapy. De novo comorbidity: comorbidity not present at baseline but newly
developed within 5 years postoperatively. Remission of type 2 diabetes:
hemoglobin A1c <42mmol/mol (6.0%), fasting glucose <100mg/dL,
and at least 1 year with no active pharmacologic therapy.
b Prop.test (R Project).
c Adjustment by step-down Bonferroni-Holm correction for multiple
comparisons for the number of subitem tests.
d χ2 Test.
e Fisher exact test.
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Table 4. Laboratory andQuality-of-LifeMeasurements
Measures
Mean (95% CI)
Mean Difference (95% CI)a
P Value Between
GroupsbSleeve Gastrectomy Roux-en-Y Gastric Bypass
Preexisting type 2 diabetes n=26 n=28
Fasting glucose, mg/dL
Baseline 139.2 (111.5 to 166.8) 120.3 (103.7 to 136.9) 18.83 (−12.90 to 50.55)
.21
Year 5 114.1 (97.2 to 131.0) 101.1 (88.8 to 113.4) 13.00 (−7.50 to 33.49)
Difference, baseline to 5 y 27.0 (5.0 to 48.9) 19.9 (2.3 to 37.5) 7.05 (−20.30 to 34.40) .61
Hemoglobin A1c
%
Baseline 7.6 (6.8 to 8.4) 7.2 (6.4 to 8.0) 0.41 (−0.64 to 1.46)
.09
Year 5 6.2 (5.9 to 6.6) 5.9 (5.7 to 6.1) 0.30 (−0.06 to 0.82)
Difference, baseline to 5 y 1.4 (0.7 to 2.1) 1.8 (1.2 to 2.4) −0.39 (−1.43 to 0.65) .45
mmol/mol
Baseline 59.7 (51.3 to 68.1) 55.7 (47.6 to 63.8) 4.04 (−7.60 to 15.68)
.09
Year 5 44.6 (40.8 to 48.4) 40.1 (37.6 to 42.6) 4.45 (−0.63 to 9.53)
Difference, baseline to 5 y 15.2 (7.4 to 23.0) 19.5 (13.5 to 25.5) −4.27 (−15.61 to 7.07) .45
Preexisting dyslipidemia n=68 n=53
Total cholesterol, mg/dL
Baseline 217.8 (206.5 to 229.0) 205.0 (192.3 to 217.7) 12.69 (−4.16 to 29.55)
.17
Year 5 195.8 (185.4 to 206.2) 186.4 (177.7 to 195.1) 9.43 (−4.13 to 22.98)
Difference, baseline to 5 y 24.5 (9.0 to 40.0) 17.1 (5.7 to 28.5) 7.39 (−14.39 to 29.17) .50
HDL-C, mg/dL
Baseline 44.9 (41.5 to 48.3) 44.3 (41.2 to 47.4) 0.61 (−3.96 to 5.18)
.33
Year 5 62.5 (58.2 to 66.8) 65.5 (60.6 to 70.4) −3.05 (−9.19 to 3.08)
Difference, baseline to 5 y 17.2 (13.9 to 20.5) 21.3 (17.6 to 25.0) 4.13 (−1.41 to 9.68) .14
Cholesterol/HDL-C ratio
Baseline 5.3 (4.8 to 5.8) 4.7 (4.3 to 5.1) 0.48 (−0.11 to 1.07)
.02
Year 5 3.3 (3.0 to 3.6) 3.0 (2.8 to 3.2) 0.38 (0.06 to 0.70)
Difference, baseline to 5 y 2.0 (1.6 to 2.4) 1.8 (1.5 to 2.1) 0.23 (−0.34 to 0.80) .42
LDL-C, mg/dL
Baseline 129.3 (121.0 to 137.7) 127.8 (117.4 to 138.2) 1.51 (−11.73 to 14.75)
.008
Year 5 116.1 (107.3 to 124.9) 101.1 (91.0 to 111.2) 14.95 (3.91 to 25.99)
Difference, baseline to 5 y 10.1 (−0.7 to 20.9) 22.8 (13.9 to 31.7) −12.75 (−31.06 to 5.57) .17
Triglycerides, mg/dL
Baseline 193.8 (167.8 to 219.8) 176.7 (150.5 to 202.9) 17.24 (−19.86 to 53.99)
.24
Year 5 172.3 (51.7 to 292.9) 97.8 (86.4 to 109.2) 74.52 (−50.38 to 199.42)
Difference, baseline to 5 y 79.9 (60.0 to 99.8) 76.8 (51.1 to 102.5) 3.12 (−32.79 to 39.15) .86
Quality of life n=101 n=104
GIQLI scorec
Baseline 99.7 (95.6 to 103.8) 99.3 (95.9 to 102.7) 0.44 (−5.74 to 6.62)
.42
Year 5 113.6 (108.9 to 118.3) 117.9 (114.8 to 121.0) −4.33 (−15.07 to 6.40)
Difference, baseline to 5 y 18.9 (13.7 to 24.1) 18.1 (14.7 to 21.5) 0.81 (−11.08 to 12.70) .89
BAROS scored
Baseline 0.1 (−0.1 to 0.3) 0.2 (−0.1 to 0.5) −0.12 (−0.52 to 0.27)
.20
Year 5 1.4 (1.1 to 1.7) 1.7 (1.5 to 1.9) −0.25 (−0.64 to 0.14)
Difference, baseline to 5 y 1.3 (1.0 to 1.6) 1.4 (1.1 to 1.7) −0.13 (−0.70 to 0.44) .66
Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol.
SI conversions: To convert total cholesterol, HDL-C, and LDL-C tommol/L,
multiply by 0.0259. To convert triglycerides to mmol/L, multiply by 0.0113.
To convert glucose tommol/L, multiply by 0.0555.
a Prop.test (R Project).
bUnpaired 2-sided t test; equal variances are not assumed. P values are not
corrected for multiple comparisons.
c Gastrointestinal Quality of Life Index (GIQLI): 36 items; scale range: 0-144
points; most desirable option: 4 points; least desirable option: 0 points; mean
score for healthy individuals, 125.8 points.8
dBariatric Analysis and Reporting Outcome System (BAROS) quality-of-life
score: 5 items; scale range: −3 to 3 points; most desirable option: 1 point for 1
item, 0.5 for the other 4 items; least desirable option: −1 point for 1 item, −0.5
point for the other 4 items.9,10
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original body weight at 5 years revealed less weight loss with
sleeve gastrectomy relative to that achieved by Roux-en-Y
gastric bypass. Although statistically significant, thesediffer-
ences were small and not clinically important.
No statistically significant difference in remission rates of
type2diabetes couldbe shown in this trial.Whilebariatric sur-
gery is recognizedasapotent treatmentoption inpatientswith
obesity and type 2 diabetes, differences between the avail-
able interventions in the efficiency to improve glycemic con-
trol in patients with and without type 2 diabetes are still un-
clear, as a certain gradient of efficiency among the surgical
interventionshasbeenreported inseveral trials.23Overall,mal-
absorptive biliopancreatic diversionhas been shown tobe the
most efficient operation in termsof type 2diabetes remission
rates (but the most radical in terms of potentially severe ad-
verseeffects), followedbyRoux-en-Ygastricbypass, sleevegas-
trectomy, and gastric banding.24 However, when comparing
sleevegastrectomywithRoux-en-Ygastricbypassheadtohead,
Roux-en-Y gastric bypass appears superior for diabetes remis-
sion rates, at least in the long term.4,25-29 For example, the
STAMPEDE trial compared best medical treatment vs sleeve
gastrectomy and Roux-en-Y gastric bypass over a period of
5 years. Although no statistically significant difference be-
tween the 2 surgical groups was found for the primary end
point of hemoglobin A1c of less than 6.0%, other end points,
such as the number of antidiabetic medications, showed su-
periority of Roux-en-Y gastric bypass vs sleeve gastrectomy.4
Asimilar outcome in termsofglycemic control inpatientswith
type 2 diabetes was also reported in 2 recent meta-analyses,
includingrandomizedtrialscomparingsleevegastrectomywith
Roux-en-Y gastric bypass only.26,29
Patients with severe, preexisting gastroesophageal reflux
disease and large hiatal hernia were not included in the
study, as Roux-en-Y gastric bypass is generally regarded as
superior to sleeve gastrectomy in these cases. Nevertheless,
many patients with morbid obesity experience intermittent
gastroesophageal reflux, which can exacerbate after sleeve
gastrectomy. In this trial, preexisting gastroesophageal
reflux disease was found to be significantly better treated by
Roux-en-Y gastric bypass compared with sleeve gastrectomy.
Moreover, worsening of reflux symptoms was more often
seen after sleeve gastrectomy, and patients with no gastro-
esophageal reflux disease at baseline more often reported de
novo reflux symptoms 5 years after sleeve gastrectomy than
after Roux-en-Y gastric bypass. In most cases, gastroesopha-
geal reflux symptoms could be treated conservatively with
proton pump inhibitors. However, in nearly 10% of patients,
pharmaceutical treatment was insufficient and sleeve gas-
trectomy had to be converted to Roux-en-Y gastric bypass
despite that during primary intervention, hiatal hernias had
always been repaired.16
Bariatric surgery is associated with a higher risk of rein-
terventions than other types of surgeries. In addition, re-
cently published reports indicate development of Barrettmu-
cosa after sleeve gastrectomy in up to 17% of asymptomatic
patients.30,31 Depending on the grade of dysplasia and the
length of the Barrett segment, the incidence of Barrett carci-
noma ranges from 0.3% to 2.4% per year.32 Longer follow-up
is needed to address the issue of gastroesophageal reflux
disease and Barrett esophagus, with endoscopic surveillance
potentiallyneeded in long-termfollow-up.Thus, recommend-
ing sleevegastrectomy toeverypatient because it seems safer,
with less perioperative morbidity and no difference in mor-
bidity up to 5 years, may be shortsighted.
Quality of life improved significantly after both proce-
duresateachtimepointcomparedwithbaseline (Table4),with
nosignificantdifferencebetween the2groups,which is incon-
trast to current literature.23
Table 5. Mortality and Adverse Events Requiring Reoperation or Endoscopic Intervention
Events
No. With Event/Total No. (%)
Absolute Difference
(95% CI)a
Sleeve
Gastrectomy
Roux-en-Y Gastric
Bypass
Early morbidity (0-30 d) 1/107 (0.9) 5/110 (4.5) −0.19 (−0.57 to 0.20)
Leak 0 1
Infection 0 3
Obstruction 1 1
Death 0 1b
Late morbidity (1 mo–5 y) 15/101 (14.9) 18/104 (17.3) −0.05 (−0.25 to 0.16)
Operative
Conversion to Roux-en-Y gastric
bypass due to gastroesophageal reflux
9 NA
Small bowel obstruction 0 2
Internal hernia 0 9
Incisional hernia 1 1
Gastroscopy necessary: laparoscopy NA 1
Severe dumping 0 3c
Insufficient weight loss 5d 2
Death 0 1e
Total reoperations or interventions 16/101 (15.8) 23/104 (22.1) −0.10 (−0.29 to 0.09)
Total mortality 0 2/104 (1.9) −0.50 (−0.82 to −0.18)
Abbreviation: NA, not applicable.
a Prop.test (R Project).
b Surgical complication (leakage).
c Two pouch revisions and 1 bypass
reversal.
d Three laparoscopic biliopancreatic
diversions (duodenal switch) and 2
conversions to laparoscopic
Roux-en-Y gastric bypass.
e Lymphoma.
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There also was no significant difference in complications
necessitating surgical or endoscopic revision within the
first 5 years postoperatively. The most frequent reason for
reoperation after sleeve gastrectomy was gastroesophageal
reflux disease, followed by insufficient weight loss. After
Roux-en-Y gastric bypass, the most frequent reinterventions
were for internal hernia in almost 10% of patients, a poten-
tially dangerous complication. In this trial, the rate of internal
hernia was rather high, whichmay be due to the fact that clo-
sure of mesenteric defects was not mandatory in the study
protocol. According to recent evidence, the incidence of
internal hernias after Roux-en-Y gastric bypass can possibly
be reduced by closure of all mesenteric defects.33,34 Other
causes for reoperation after Roux-en-Y gastric bypass were
late dumping or small bowel obstruction, complications
that rarely occur after sleeve gastrectomy. Thus, the types of
complications are different, but the frequency is not statisti-
cally different.
This study has several limitations. First, the study is un-
derpowered for the exploratory end point of type 2 diabetes
remission.Althoughno significantdifferenceswere foundbe-
tweenthe2procedures regarding their antidiabeticeffects, this
trial does not allow for firmconclusions on the absence of dif-
ferences.Second,because randomizedtrialsareconductedun-
der idealized and rigorously controlled conditions, their gen-
eralizability might be compromised. The willingness to
participate in a randomized trial might per se also lead to pa-
tient selection bias. However, the study outcomes are in line
withoutcomes seen inunselectedbariatric cohorts andcanbe
considered to be generalizable.
In addition, the protocol did not include an upper limit for
BMI, and there were a few patients with BMI above 60 in both
groups. This trial cannot answer the question whether pa-
tients with extremely high BMImay have greater benefit from
a staged concept with initial sleeve gastrectomy followed
by Roux-en-Y gastric bypass or biliopancreatic diversion.
Patientsandstaffwerenotblindedtothetypeofoperation.Both
operations have specific complications (eg, internal hernia,
which isonlypossible afterRoux-en-Ygastric bypass) andphy-
sicians inchargeaswell aspatientsmustknowwhatkindofop-
eration was carried out. In our opinion, blinding would have
been unethical.
Conclusions
Among patients with morbid obesity, there was no signifi-
cantdifference inexcessBMI lossbetween laparoscopic sleeve
gastrectomy and laparoscopic Roux-en-Y gastric bypass at 5
years of follow-up after surgery.
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